Shenzhen - Delayed Quote CNY

Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. (300937.SZ)

Compare
21.66 +0.07 (+0.32%)
At close: 3:04 PM GMT+8
Loading Chart for 300937.SZ
DELL
  • Previous Close 21.59
  • Open 21.58
  • Bid 21.66 x --
  • Ask 21.68 x --
  • Day's Range 21.40 - 21.77
  • 52 Week Range 17.83 - 42.15
  • Volume 575,700
  • Avg. Volume 1,750,594
  • Market Cap (intraday) 2.072B
  • Beta (5Y Monthly) 0.17
  • PE Ratio (TTM) 55.54
  • EPS (TTM) 0.39
  • Earnings Date --
  • Forward Dividend & Yield 0.22 (1.02%)
  • Ex-Dividend Date Jun 13, 2024
  • 1y Target Est --

Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. distributes generic drugs and Chinese medicines in China. The company offers medications in the areas of respiratory, anti-inflammatory, five senses, skin and external, digestive, hepatobiliary system, rehabilitation and tranquility, women, pediatrics, cardiovascular and neurological, endocrine system, rheumatoid bone injury, and others. It also provides special compound preparations, biological products, Chinese herbal medicines, and non-medicine products. The company was founded in 2007 and is based in Chengdu, China.

www.hezongyy.com

1,114

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 300937.SZ

Performance Overview: 300937.SZ

Trailing total returns as of 6/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

300937.SZ
31.13%
SSE Composite Index
1.94%

1-Year Return

300937.SZ
32.38%
SSE Composite Index
6.22%

3-Year Return

300937.SZ
60.11%
SSE Composite Index
15.52%

5-Year Return

300937.SZ
41.46%
SSE Composite Index
15.13%

Compare To: 300937.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300937.SZ

Valuation Measures

Annual
As of 6/13/2024
  • Market Cap

    2.07B

  • Enterprise Value

    2.11B

  • Trailing P/E

    55.87

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.46

  • Price/Book (mrq)

    2.39

  • Enterprise Value/Revenue

    0.46

  • Enterprise Value/EBITDA

    42.45

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.82%

  • Return on Assets (ttm)

    1.55%

  • Return on Equity (ttm)

    4.03%

  • Revenue (ttm)

    4.55B

  • Net Income Avi to Common (ttm)

    37.12M

  • Diluted EPS (ttm)

    0.39

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    382.47M

  • Total Debt/Equity (mrq)

    47.91%

  • Levered Free Cash Flow (ttm)

    -126.18M

Research Analysis: 300937.SZ

Company Insights: 300937.SZ

Research Reports: 300937.SZ

People Also Watch